WO2015197193A3 - Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies - Google Patents

Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies Download PDF

Info

Publication number
WO2015197193A3
WO2015197193A3 PCT/EP2015/001293 EP2015001293W WO2015197193A3 WO 2015197193 A3 WO2015197193 A3 WO 2015197193A3 EP 2015001293 W EP2015001293 W EP 2015001293W WO 2015197193 A3 WO2015197193 A3 WO 2015197193A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
jnk inhibitor
various diseases
inhibitor molecules
new use
Prior art date
Application number
PCT/EP2015/001293
Other languages
English (en)
Other versions
WO2015197193A2 (fr
Inventor
Jean-Marc Combette
Catherine Deloche
Original Assignee
Xigen Inflammation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/001737 external-priority patent/WO2014206564A1/fr
Priority claimed from PCT/EP2014/002723 external-priority patent/WO2015197097A1/fr
Application filed by Xigen Inflammation Ltd. filed Critical Xigen Inflammation Ltd.
Priority to EP15734295.7A priority Critical patent/EP3160989A2/fr
Priority to JP2016575150A priority patent/JP6843625B2/ja
Priority to US15/321,904 priority patent/US20170128516A1/en
Publication of WO2015197193A2 publication Critical patent/WO2015197193A2/fr
Publication of WO2015197193A3 publication Critical patent/WO2015197193A3/fr
Priority to US16/430,697 priority patent/US11331364B2/en
Priority to US17/719,068 priority patent/US20220280591A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de nouvelles molécules inhibitrices de JNK et leur utilisation dans une méthode de traitement thérapeutique du corps d'un humain ou d'un animal.
PCT/EP2015/001293 2013-06-26 2015-06-26 Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies WO2015197193A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP15734295.7A EP3160989A2 (fr) 2014-06-26 2015-06-26 Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies
JP2016575150A JP6843625B2 (ja) 2013-06-26 2015-06-26 様々な疾患の処置のためのｊｎｋ阻害剤分子の新規使用
US15/321,904 US20170128516A1 (en) 2013-06-26 2015-06-26 Use for JNK Inhibitor Molecules for Treatment of Various Diseases
US16/430,697 US11331364B2 (en) 2014-06-26 2019-06-04 Use for JNK inhibitor molecules for treatment of various diseases
US17/719,068 US20220280591A1 (en) 2013-06-26 2022-04-12 Use For JNK Inhibitor Molecules For Treatment Of Various Diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2014/001737 WO2014206564A1 (fr) 2013-06-26 2014-06-26 Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
EPPCT/EP2014/001737 2014-06-26
EPPCT/EP2014/002723 2014-10-08
PCT/EP2014/002723 WO2015197097A1 (fr) 2014-06-26 2014-10-08 Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/321,904 A-371-Of-International US20170128516A1 (en) 2013-06-26 2015-06-26 Use for JNK Inhibitor Molecules for Treatment of Various Diseases
US16/430,697 Continuation US11331364B2 (en) 2013-06-26 2019-06-04 Use for JNK inhibitor molecules for treatment of various diseases

Publications (2)

Publication Number Publication Date
WO2015197193A2 WO2015197193A2 (fr) 2015-12-30
WO2015197193A3 true WO2015197193A3 (fr) 2016-02-25

Family

ID=54938878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/001293 WO2015197193A2 (fr) 2013-06-26 2015-06-26 Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies

Country Status (2)

Country Link
EP (1) EP3160989A2 (fr)
WO (1) WO2015197193A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072228A1 (fr) 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
CA2807036C (fr) 2010-10-14 2018-01-16 Xigen S.A. Utilisation d'inhibiteurs peptidiques, aptes a penetrer dans les cellules, de la voie de transduction du signal jnk pour le traitement de maladies oculaires inflammatoires chroniques ou non-chroniques
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
CA2903275A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs peptidiques permeables aux cellules de la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
CA2987365A1 (fr) * 2015-06-26 2016-12-29 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs peptidiques a permeabilite cellulaire de la voie de transduction du signal jnk pour le traitement de troubles cognitifs legers
US10793601B2 (en) * 2016-04-28 2020-10-06 National University Of Singapore Therapeutic spalt-like transcription factor 4 (SALL4) peptide
KR101943978B1 (ko) * 2017-12-28 2019-01-30 주식회사 하이센스바이오 신규한 펩타이드
UA126941C2 (uk) * 2018-03-29 2023-02-22 С.І.С. Шулов Інновейтів Сайєнс Лтд. Фармацевтичні композиції для інгібування запальних цитокінів
CN109303782A (zh) * 2018-10-24 2019-02-05 厦门大学 Jnk-in-8在制备干性年龄相关性黄斑变性的神经保护剂中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031280A2 (fr) * 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
WO2009143865A1 (fr) * 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2011160653A1 (fr) * 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
WO2013091670A1 (fr) * 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031280A2 (fr) * 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
WO2009143865A1 (fr) * 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2011160653A1 (fr) * 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
WO2013091670A1 (fr) * 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2013091896A1 (fr) * 2011-12-21 2013-06-27 Xigen Inflammation Ltd. Nouvelles molécules inhibitrices de la jnk pour le traitement de diverses maladies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CUI JIE ET AL: "JNK pathway: diseases and therapeutic potential.", ACTA PHARMACOLOGICA SINICA MAY 2007, vol. 28, no. 5, May 2007 (2007-05-01), pages 601 - 608, XP002743937, ISSN: 1671-4083 *

Also Published As

Publication number Publication date
WO2015197193A2 (fr) 2015-12-30
EP3160989A2 (fr) 2017-05-03

Similar Documents

Publication Publication Date Title
WO2015197193A3 (fr) Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies
HUE049237T2 (hu) Készítmények a bõr sérülései, rendellenességei és betegségei kezelési eljárásaiban történõ alkalmazásra
EP3458574A4 (fr) Cellule souche mésenchymateuse et son utilisation pour le traitement des lésions musculaires et des maladies associées aux muscles
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
IL267210A (en) Amino acid compounds and methods for treating muscle diseases and disorders
WO2015173633A3 (fr) Marqueurs de thérapie hdl
WO2014176128A3 (fr) Compositions et méthodes pour le traitement et le diagnostic de la grippe
EP3686200A3 (fr) Composés hétérocycles bicycliques et leurs utilisations en thérapie
EP3030275A4 (fr) Procédé de traitement de maladies des artères périphériques des membres inférieurs
PT3405215T (pt) Métodos para o tratamento da doença de danon e outros transtornos da autofagia
EP3268007A4 (fr) Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
EP3030276A4 (fr) Procédé de traitement de maladies des artères périphériques des membres inférieurs
EP4272839A3 (fr) Traitement de la rhinite allergique à l'aide d'une association de mométasone et d'olopatadine
EP3030274A4 (fr) Procédé de traitement de maladies des artères périphériques des membres inférieurs
IL251530B (en) Use of cannabinoids in the treatment of skeletal muscle wasting diseases
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
WO2016004413A3 (fr) Inhibiteurs de la gls1 pour le traitement de maladies
SI3722291T1 (sl) Indolinonske spojine in njihova uporaba pri zdravljenju fibrotičnih bolezni
JOP20190056B1 (ar) مركبات للاستخدام في علاج القصور الكلوي الحاد
EP3185862A4 (fr) Composés d'analogues de la métallothionéine de protection, leurs compositions et leur utilisation dans le traitement de maladies pathogènes
PT3153511T (pt) Derivado de 2-acilaminotiazole para utilização na prevenção ou tratamento de doenças da bexiga/trato urinário
EP2949651A4 (fr) Benzothiazoles substitués et leurs appllications thérapeutiques pour le traitement de maladies humaines
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
EP3549582A3 (fr) Nouveaux analogues de la capsazépine pour le traitement du cancer et d'autres maladies prolifératives
PL3515409T3 (pl) Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15734295

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2016575150

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15321904

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015734295

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015734295

Country of ref document: EP